Connect Biopharma Holdings Ltd Total Assets
Connect Biopharma Holdings Ltd total assets. Based on the latest financial reports, Connect Biopharma Holdings Ltd (CNTB) holds total assets worth $43.47 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Connect Biopharma Holdings Ltd for the company's overall valuation and market capitalisation.
Total Assets of Connect Biopharma Holdings Ltd (2018–2025)
Total assets of Connect Biopharma Holdings Ltd from 2018 to 2025. This chart illustrates how Connect Biopharma Holdings Ltd's total assets have evolved over time, based on quarterly financial data. See Connect Biopharma Holdings Ltd stock price for real-time trading data and today's change.
Connect Biopharma Holdings Ltd - Asset Composition Analysis
Connect Biopharma Holdings Ltd Total Assets Breakdown (December 2025)
Connect Biopharma Holdings Ltd total assets breakdown as of December 2025. Connect Biopharma Holdings Ltd's total assets of $43.47 Million consist of 90.8% current assets and 9.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 68.4% |
| Accounts Receivable | $161.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $45.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Connect Biopharma Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Connect Biopharma Holdings Ltd (CNTB) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Connect Biopharma Holdings Ltd's current assets represent 90.8% of total assets in 2025, a decrease from 98.3% in 2018.
- Cash Position: Cash and equivalents constituted 68.4% of total assets in 2025, down from 88.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Connect Biopharma Holdings Ltd Competitors by Total Assets
Key competitors of Connect Biopharma Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Connect Biopharma Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.37 | 7.24 | 23.15 |
| Quick Ratio | 2.37 | 7.24 | 23.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $22.32 Million | $67.02 Million | $48.01 Million |
Connect Biopharma Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between Connect Biopharma Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.84 |
| Latest Market Cap to Assets Ratio | 0.87 |
| Asset Growth Rate (YoY) | -44.6% |
| Total Assets | $56.08 Million |
| Market Capitalization | $48.75 Million USD |
Valuation Analysis
Near Book Valuation: The market values Connect Biopharma Holdings Ltd's assets close to their book value (0.87x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Connect Biopharma Holdings Ltd's assets decreased by 44.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Connect Biopharma Holdings Ltd (2018–2025)
The table below shows the annual total assets of Connect Biopharma Holdings Ltd from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $56.08 Million | -44.64% |
| 2024-12-31 | $101.28 Million | -20.48% |
| 2023-12-31 | $127.38 Million | -26.80% |
| 2022-12-31 | $174.01 Million | -40.21% |
| 2021-12-31 | $291.05 Million | +1044.19% |
| 2020-12-31 | $25.44 Million | +229.27% |
| 2019-12-31 | $7.73 Million | -88.85% |
| 2018-12-31 | $69.29 Million | -- |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.